MedTrace Logo

The Cardiovascular Benefits of Resistance Training and Dark Chocolate in Female Adults

NCT06908941 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2025-04-04

No results posted yet for this study

Summary

This study investigates the effects of 85% dark chocolate supplementation on vascular function and nitric oxide (NO) levels during high-intensity resistance exercise in healthy women across menstrual phases. Using a randomized crossover design, 31 women consumed either dark chocolate or milk chocolate before exercising during the early follicular and mid-luteal phases. Vascular markers, including pulse wave velocity (ftPWV), arterial stiffness, blood pressure, and plasma NO levels, were measured at multiple time points.

Conditions

  • Vascular Function in Healthy Volunteers

Interventions

DIETARY_SUPPLEMENT

dark chocolate

Participants consumed 85% dark chocolate (1g/kg body weight) before high-intensity resistance exercise during the early follicular (days 2-5) and mid-luteal (days 18-24) phases of two menstrual cycles. Finger-toe pulse wave velocity (ftPWV), arterial stiffness, blood pressure, and plasma NO levels were measured at rest, 2 hours after chocolate consumption (baseline), immediately post-exercise (T0), and at 60 (T60) and 120 (T120) minutes post-exercise.

DIETARY_SUPPLEMENT

milk chocolate

Participants consumed milk chocolate (1g/kg body weight) before high-intensity resistance exercise during the early follicular (days 2-5) and mid-luteal (days 18-24) phases of two menstrual cycles. Finger-toe pulse wave velocity (ftPWV), arterial stiffness, blood pressure, and plasma NO levels were measured at rest, 2 hours after chocolate consumption (baseline), immediately post-exercise (T0), and at 60 (T60) and 120 (T120) minutes post-exercise.

BEHAVIORAL

high-intensity resistance exercise

Participants performed high-intensity resistance exercise during the early follicular (days 2-5) and mid-luteal (days 18-24) phases of two menstrual cycles.

Sponsors & Collaborators

  • National Cheng Kung University

    lead OTHER

Principal Investigators

  • Cheng-Shiun He Professor · National Chung Cheng University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
30 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-09-01
Primary Completion
2023-12-31
Completion
2024-07-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06908941 on ClinicalTrials.gov